Susann Theile
About
Susann Theile is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine.
According to data from OpenAlex, Susann Theile has authored 26 papers receiving a total of 303 indexed citations (citations by other indexed papers that have themselves been cited), including 22 papers in Oncology, 7 papers in Molecular Biology and 5 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Susann Theile's work include Pancreatic and Hepatic Oncology Research (12 papers), Cancer Immunotherapy and Biomarkers (9 papers) and Colorectal Cancer Treatments and Studies (8 papers). Susann Theile is often cited by papers focused on Pancreatic and Hepatic Oncology Research (12 papers), Cancer Immunotherapy and Biomarkers (9 papers) and Colorectal Cancer Treatments and Studies (8 papers). Susann Theile collaborates with scholars based in Denmark, United States and Germany. Susann Theile's co-authors include Dorte Nielsen, Inna M. Chen, Julia S. Johansen, Inge Marie Svane, Torben Lorentzen, Benny Vittrup Jensen, Kasper Madsen, Finn Ole Larsen, Jane Preuss Hasselby and Poul Geertsen and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Clinical Cancer Research.
In The Last Decade
Susann Theile
24 papers receiving 301 citations
Peers
Susann Theile
Hiroaki Soyama Japan
Marta Capelán United Kingdom
Jordan T. Lee United States
Utku Oflazoğlu Türkiye
Gilles Freyer France
Anna Rachelle Mislang Australia
Nedal Bukhari Saudi Arabia
Georg Holgersson Sweden
Aine O’Reilly Ireland
Citations per year, relative to Susann Theile Susann Theile (= 1×)
peers
Hiroaki Soyama
Countries citing papers authored by Susann Theile
Since
Specialization
Citations
This map shows the geographic impact of Susann Theile's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Susann Theile with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Susann Theile more than expected).
Fields of papers citing papers by Susann Theile
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Susann Theile. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Susann Theile. The network helps show where Susann Theile may publish in the future.
Co-authorship network of co-authors of Susann Theile
This figure shows the co-authorship network connecting the top 25 collaborators of Susann Theile. A scholar is included among the top collaborators of Susann Theile based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Susann Theile. Susann Theile is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Hruban, Carolyn, Daniel C. Bruhm, Inna M. Chen, et al.. (2025). Genome-wide analyses of cell-free DNA for therapeutic monitoring of patients with pancreatic cancer. Science Advances. 11(21). eads5002–eads5002.
2.
Chen, Inna M., Julia S. Johansen, Susann Theile, et al.. (2025). Randomized Phase II Study of Nab-Paclitaxel and Gemcitabine With or Without Tocilizumab as First-Line Treatment in Advanced Pancreatic Cancer: Survival and Cachexia. Journal of Clinical Oncology. 43(18). 2107–2118.
3.
Chen, I‐Ming, Susann Theile, Kasper Madsen, et al.. (2025). A phase II study of nivolumab, ipilimumab, and radiation in combination with influenza vaccine in patients with pancreatic cancer (INFLUENCE). Immuno-Oncology Technology. 26. 101054–101054.
4.
Johansen, Julia S., Finn Ole Larsen, Susann Theile, et al.. (2024). Nivolumab with or without Ipilimumab Combined with Stereotactic Body Radiotherapy in Patients with Metastatic Biliary Tract Cancer: A Randomized Phase 2 Study. Clinical Cancer Research. 30(16). 3428–3437.
5.
Persson, Gitte Fredberg, Susann Theile, Dorte Nielsen, et al.. (2023). Randomised phase II trial of stereotactic body radiotherapy in combination withcheckpoint inhibitors in metastatic castration-resistantprostate cancer (CheckPRO): a study protocol. BMJ Open. 13(1). e063500–e063500.
6.
Johansen, Astrid Z., Jessica Xin Hjaltelin, Susann Theile, et al.. (2023). Plasma YKL-40 is associated with prognosis in patients with metastatic pancreatic cancer receiving immune checkpoint inhibitors in combination with radiotherapy. Frontiers in Immunology. 14. 1228907–1228907.
7.
Chen, Inna M., Julia S. Johansen, Susann Theile, et al.. (2023). Randomized phase 2 study of nab-paclitaxel and gemcitabine with or without tocilizumab as first-line treatment in patients with advanced pancreatic cancer (PACTO).. Journal of Clinical Oncology. 41(16_suppl). 4147–4147.
8.
Chen, Inna M., Julia S. Johansen, Susann Theile, et al.. (2022). Randomized Phase II Study of Nivolumab With or Without Ipilimumab Combined With Stereotactic Body Radiotherapy for Refractory Metastatic Pancreatic Cancer (CheckPAC). Journal of Clinical Oncology. 40(27). 3180–3189.
9.
Lund, Cecilia Margareta, Marta Kramer Mikkelsen, Susann Theile, et al.. (2022). Age-related Differences in Recall of Information and Handling of Chemotherapy-related Side Effects in Cancer Patients: The ReCap Study. The Oncologist. 27(2). e185–e193.
10.
Chen, Inna M., Marco Donia, Christopher A. Chamberlain, et al.. (2022). Phase 2 study of ipilimumab, nivolumab, and tocilizumab combined with stereotactic body radiotherapy in patients with refractory pancreatic cancer (TRIPLE-R). European Journal of Cancer. 180. 125–133.
11.
Holmstroem, Rikke B., Ole Haagen Nielsen, Søren Jacobsen, et al.. (2022). COLAR: open-label clinical study of IL-6 blockade with tocilizumab for the treatment of immune checkpoint inhibitor-induced colitis and arthritis. Journal for ImmunoTherapy of Cancer. 10(9). e005111–e005111.
12.
Nielsen, Ole Haagen, Søren Jacobsen, Lene Riis, et al.. (2021). 1685P COLAR: Results from an intervention study investigating IL-6 blockade with tocilizumab for treatment of immune checkpoint inhibitor induced colitis and arthritis. Annals of Oncology. 32. S1180–S1180.
13.
Mikkelsen, Marta Kramer, Cecilia Margareta Lund, Anders Vinther, et al.. (2021). Effects of a 12-Week Multimodal Exercise Intervention Among Older Patients with Advanced Cancer: Results from a Randomized Controlled Trial. The Oncologist. 27(1). 67–78.
14.
Theile, Susann, et al.. (2020). Cancer patients, physicians, and nurses differ in their attitudes toward the decisional role in do-not-resuscitate decision-making. Supportive Care in Cancer. 28(12). 6057–6066.
15.
Nilsson, Sven, Alexander Stein, Christian Rolfo, et al.. (2020). Selinexor (KPT-330), an Oral Selective Inhibitor of Nuclear Export (SINE) Compound, in Combination with FOLFOX in Patients with Metastatic Colorectal Cancer (mCRC) - Final Results of the Phase I Trial SENTINEL. Current Cancer Drug Targets. 20(10). 811–817.
16.
Kümler, Iben, Rikke Løvendahl Eefsen, Peter G. Sørensen, et al.. (2019). An open label phase 1 study evaluation safety, tolerability, and maximum tolerated dose of oral administration of irinotecan in combination with capecitabine. Cancer Chemotherapy and Pharmacology. 84(2). 441–446.
17.
Kümler, Iben, Peter G. Sørensen, Jesper Andreas Palshof, et al.. (2018). Oral administration of irinotecan in patients with solid tumors: an open-label, phase I, dose escalating study evaluating safety, tolerability and pharmacokinetics. Cancer Chemotherapy and Pharmacology. 83(1). 169–178.
18.
Jensen, Bjørn K., Susann Theile, Finn Ole Larsen, et al.. (2018). Hepatic arterial therapy with oxaliplatin and systemic capecitabine for patients with liver metastases from breast cancer. The Breast. 43. 113–119.
19.
Fiedler, Walter, Michael Heuser, Jörg Chromik, et al.. (2016). Phase II Results of Ara-C and Idarubicin in Combination with the Selective Inhibitor of Nuclear Export (SINE) Compound Selinexor (KPT-330) in Patients with Relapsed or Refractory AML. Blood. 128(22). 341–341.
20.
Fiedler, Walter, Jörg Chromik, Maxim Kebenko, et al.. (2015). Selinexor, ARA-C and Idarubicin: An Effective and Tolerable Combination in Patients with Relapsed/Refractory AML: A Multicenter Phase II Study. Blood. 126(23). 3789–3789.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Hiroaki Soyama Breakdown of academic impact, for papers by Marta Capelán Breakdown of academic impact, for papers by Jordan T. Lee Breakdown of academic impact, for papers by Utku Oflazoğlu Breakdown of academic impact, for papers by Gilles Freyer Breakdown of academic impact, for papers by Anna Rachelle Mislang Breakdown of academic impact, for papers by Nedal Bukhari Breakdown of academic impact, for papers by Antonino Carmelo Tralongo Breakdown of academic impact, for papers by Georg Holgersson Breakdown of academic impact, for papers by Aine O’Reilly